Figure 4.

PRMT5 KD produces less aggressive tumors with greater survival in a mouse PDX model of PHGG. A, Kaplan–Meier survival curve showing that mice orthotopically injected with BT245 patient-derived tumor cells with PRMT5 KD survive 2.5–3 times longer than mice injected with empty vector control tumor cells, n = 8 mice per arm. B, MRI images of empty vector (control) and PRMT5 KD tumors; arrowheads show enhancement of tumor areas. C, Bioluminescence images showing tumor progression. D, Histologic sections with H&E staining showing representative tumors from PRMT5 KD and empty vector control mice. E, Ki-67 staining (top) and quantification showing a greater number of proliferating cells in PRMT5 KD vs. empty vector control tumors (P < 0.05). F, In vitro, PHGG cells with PRMT5 KD are more susceptible to RT than empty vector control cells (N = 3 for all data points, and error bars not shown were too close to the central estimate to display). G, Kaplan–Meier survival curve showing no significant differences in survival of mice treated with the PRMT5 inhibitor vs. vehicle control with and without RT (BT245 PDX model). EV, empty vector; H&E, hematoxylin and eosin; Veh, vehicle.